Narrative Review: Statin-Related Myopathy
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid-binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Individual patient drug–placebo clinical trials have been suggested as an approach to confirming diagnosis of SAMS,31 but are not feasible in the routine outpatient setting.”
In the citing paper
“In a meta-analysis of 21 RCTs700) and in another meta-analysis of 30 RCTs701), the incidence rate of muscles-related adverse reactions with statin use was not found to be significantly different from that with a placebo.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [700]
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“Recently, a common DNA polymorphism in the SLCO1B1 gene encoding organic anion-transporting polypeptide was strongly associated with simvastatin-associated myopathy (55), but this association was not seen in patients with atorvastatinassociated myopathy (59).”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Keller, S., Bann, C. M., Dodd, S. L., Schein, J., Mendoza, T. R., & Cleeland, C. S. (2004) · The Clinical Journal of Pain · doi:10.1097/00002508-200409000-00005 · Cited by 1,233 · cited 1×
“Pain was assessed through the Brief Pain Inventory (86), which provided measures of pain severity and interference in daily activities.”
MethodBruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · cited 10×
“that prevented moderate exertion during daily activity, demonstrating a potential wider effect of statin-related myopathy on quality of life (33).”
BackgroundResultInfluentialACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859 · cited 2×
“Cyclosporine is a potent inhibitor of not only CYP3A4 but also several membrane transporters, and it increases the pharmacokinetic area under the curve of statins by 2- to 25fold, with many reported cases of rhabdomyolysis (44).”
BackgroundStatin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808
Ballantyne, C. M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L. J., Suresh, R., Sun, S., LeBeaut, A. P., Sager, P. T., & Veltri, E. P. (2003) · Circulation · doi:10.1161/01.cir.0000068312.21969.c8 · Cited by 687
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626 · cited 2×
“No case of fatal rhabdomyolysis has been reported yet with fluvastatin (37).”
Background
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationKinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Rhabdomyolysis: pathogenesis, diagnosis, and treatment.
Torres, P. A., Helmstetter, J. A., Kaye, A. M., & Kaye, A. D. (2015) · PubMed Central · Cited by 619
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
“It seems that this phenomenon might occur in 10–15% of patients [11, 12], however only very few (< 1%) develop serious side-effects such as myopathy, myositis or rhabdomyolysis [12].”
BackgroundInfluentialKoren, M. J., Scott, R., Kim, J. B., Knusel, B., Liu, T., Lei, L., Bolognese, M., & Wasserman, S. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61771-1 · Cited by 366
Metadata
- Authors
- Joy, T. R., & Hegele, R. A.
- Affiliations
- Western University (CA)
- Corresponding author
- Joy, Tisha R.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-06-16
- Volume
- 150
- Issue
- 12
- Pages
- 858-868
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2103873642
- Cited by
- 453
- References
- 83
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 25 · 2023: 15 · 2022: 12 · 2021: 13 · 2020: 13 · 2019: 20 · 2018: 25 · 2017: 29 · 2016: 39 · 2015: 41 · 2014: 41 · 2013: 47 · 2012: 33
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- statin intolerance, statin-induced myalgia, rhabdomyolysis, statin switching, fluvastatin, rosuvastatin, ezetimibe, bile acid sequestrants, coenzyme Q10 supplementation, LDL cholesterol targets, statin adverse effects
- MeSH terms
- Diagnosis, Differential, Humans, Muscular Diseases, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Narrative Review: Statin-Related Myopathy. https://app.cochat.ai/papers/10.7326/0003-4819-150-12-200906160-00009
- The paper
- Joy, T. R., & Hegele, R. A. (2009). Narrative Review: Statin-Related Myopathy. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-12-200906160-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.